Video

Dr. Sandler on Candidates for Liase Inhibitor Clinical Trials

Author(s):

Howard M. Sandler, MD

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses candidates for liase inhibitor clinical trials.

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses candidates for liase inhibitor clinical trials, the trial would look at gleason 8 or 9 tumors, locally advanced, T3 tumors that extend outside of the prostate. These are generally men who are not candidates for surgery and would benefit from other options.

Related Videos
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD
Brandon Huffman, MD
Sattva S. Neelapu, MD
Related Content
W. Robert Lee, MD, MEd, MS
June 12th 2024

Hypofractionation is Noninferior to Conventional Fractionation Radiotherapy in Low-Risk Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Daniel P. Petrylak, MD, of Yale School of Medicine
June 10th 2024

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Ronald C. Chen, MD, MPH, FASCO, FASTRO
June 6th 2024

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

Stephen J. Freedland, MD
June 5th 2024

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC